Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511783 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01511783 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 50 participants.
The verdict
NCT01511783, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.
Interventions
- DRUG Placebo
- DRUG E2609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511783
The ClinicalTrials.gov registry entry for NCT01511783 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01511783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511783 about?
NCT01511783 is a clinical study titled "Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects". The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.
What is the current status of trial NCT01511783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01511783?
The interventions under investigation include: Placebo (DRUG), E2609 (DRUG).
Who is sponsoring clinical trial NCT01511783?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.